Methotrexate Sodium Injection
Brand names: Methotrexate
Category: Oncology, Rheumatology
FDA status: Current · Last FDA update: Sep 22, 2026 · First posted: Mar 13, 2023 (in shortage 3 years 6 months) · 5 manufacturers, 14 listed presentations
As of Sep 22, 2026, the FDA lists Methotrexate Sodium Injection as currently in shortage. Of 14 manufacturer presentations, 4 Unavailable, 3 Limited, 7 Available.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) NDC 0143-9830-01 |
Hikma Pharmaceuticals USA, Inc. | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. |
| Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) NDC 63323-122-50 |
Fresenius Kabi USA, LLC | Available | Check wholesaler for inventory |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) NDC 16729-277-30 |
Accord Healthcare Inc. | Unavailable | Estimated recovery: late September 2026; Short dated inventory with expiry of 09/30/27 available |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) NDC 16729-277-35 |
Accord Healthcare Inc. | Unavailable | Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: TBD |
| Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) NDC 0143-9519-10 |
Hikma Pharmaceuticals USA, Inc. | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) NDC 0703-3671-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: October 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) NDC 0703-3678-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: October 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) NDC 0703-3675-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: December 2026 |
| Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) NDC 63323-123-10 |
Fresenius Kabi USA, LLC | Available | Check wholesaler for inventory |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) NDC 61703-124-40 |
Hospira, Inc., a Pfizer Company | Available | - |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) NDC 61703-408-25 |
Hospira, Inc., a Pfizer Company | Available | - |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) NDC 61703-408-41 |
Hospira, Inc., a Pfizer Company | Available | - |
| Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) NDC 61703-350-10 |
Hospira, Inc., a Pfizer Company | Available | - |
| Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) NDC 61703-350-38 |
Hospira, Inc., a Pfizer Company | Available | - |
Related medications in shortage
Other Oncology, Rheumatology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Methotrexate Sodium Injection (FDA data as of Sep 22, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Methotrexate Sodium Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/methotrexate-sodium-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).